Predicting relapses in patients with autoimmune vascular disease

Patients with an autoimmune disorder called antineutrophil cytoplasmic antibody-associated vasculitis produce antibodies that damage blood vessels in the body. In some cases, patients' antibodies target a protein called myeloperoxidase. New research published in Arthritis & Rheumatology indicates that for patients in remission, reappearance of antibodies against myeloperoxidase is a sign that patients will experience a relapse of their disease.

The findings suggest that patients should undergo routine monitoring of against myeloperoxidase.

"Our results could be helpful in daily clinical practice related to antineutrophil cytoplasmic antibody-associated vasculitis," said co-author Dr. Ken-Ei Sada, of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Japan.

More information: Arthritis & Rheumatology, DOI: 10.1002/art.40538

Provided by Wiley
Citation: Predicting relapses in patients with autoimmune vascular disease (2018, May 23) retrieved 4 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Blood test helps predict relapse in patients with autoimmune disease affecting the kidneys


Feedback to editors